Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) and SeaStar Medical (NASDAQ:ICU – Get Free Report) are both healthcare companies, but which is the better investment? We compare the two businesses based on earnings, analyst recommendations, dividends, valuation, institutional holdings, profitability and risk strength.
Revenue and Ratings
This table compares Tandem Diabetes Care and SeaStar Medical’s total revenue, earnings per share, and valuation.
| Earnings | Price/Sales Ratio | Net income | Earnings per Share | Price Earnings Ratio | |
| Tandem Diabetes Care | $747.72 million | 3.70 | -$222.61 million | ($2.17) | -19.74 |
| Sea Star Medical | N/A | N/A | -$26.23 million | ($25.00) | -0.16 |
SeaStar Medical has lower sales but higher profits than Tandem Diabetes Care. Tandem Diabetes Care has a lower price-to-earnings ratio than SeaStar Medical, suggesting that Tandem Diabetes Care is currently the more affordable of the two stocks.
Risk and Volatility
Tandem Diabetes Care has a beta of 1.26, meaning its stock price is 26% more volatile than the S&P 500. In comparison, SeaStar Medical’s beta is -1.03, meaning its stock price is 203% less volatile than the S&P 500.
Institutional and insider ownership
1.7% of SeaStar Medical’s shares are owned by institutional investors. 2.2% of Tandem Diabetes Care’s shares are owned by insiders. In comparison, 3.0% of SeaStar Medical’s shares are owned by insiders. Strong institutional ownership indicates that endowments, hedge funds, and large asset managers believe that the stock will outperform the market in the long term.
Profitability
This table compares the net profit margins, return on equity, and return on assets of Tandem Diabetes Care and SeaStar Medical.
| Net income | Return on Equity | Return on Assets | |
| Tandem Diabetes Care | -18.37% | -34.38% | -10.91% |
| Sea Star Medical | N/A | N/A | -725.48% |
Analyst Recommendations
This is a summary of MarketBeat’s current ratings and recommendations for Tandem Diabetes Care and SeaStar Medical.
| Sell rating | Ratings on hold | Purchase Rating | Strong Buy Rating | Evaluation score | |
| Tandem Diabetes Care | 0 | 1 | 12 | 0 | 2.92 |
| Sea Star Medical | 0 | 0 | 0 | 0 | N/A |
Tandem Diabetes Care’s current consensus price target is $51.25, suggesting an upside potential of 19.66%. With Tandem Diabetes Care’s upside potential being high, equity research analysts clearly consider Tandem Diabetes Care to be a better bet than SeaStar Medical.
About Tandem Diabetes Care
(Get your free report)
Tandem Diabetes Care, Inc., a medical device manufacturer, designs, develops, and commercializes technology solutions for people with diabetes in the United States and worldwide. The company’s flagship products are the t:slim X2 insulin delivery system, a pump platform that manages insulin delivery and displays continuous glucose monitoring sensor information directly on the pump’s home screen, and the Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells disposable products, such as cartridges for storing and delivering insulin and infusion sets that connect the insulin pump to the user’s body. In addition, the company offers Tandem Device Updater, which is used to update pump software from a personal computer; Tandem Source, a web-based data management platform that visually displays diabetes care management data from pumps, integrated CGMs, and supported glucose meters; and Sugarmate, a mobile app that visualizes diabetes care data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
About Sea Star Medical
(Get your free report)
SeaStar Medical Holding Corporation, a medical device company, is developing platform therapies in the United States that reduce the effects of hyper-inflammation in vital organs. The company provides an inflammatory response to prevent infection and repair damaged tissues in the body. The company is developing products in various therapeutic areas, including acute kidney injury in children and adults due to CRRT, cardiorenal syndrome in congestive heart failure, myocardial collapse in end stage renal disease, and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
Receive daily Tandem Diabetes Care news and reviews –Enter your email address below to receive a concise summary of the latest news and analyst ratings on Tandem Diabetes Care and related companies every day via MarketBeat.com’s free email newsletter.
